Context: Through the expression of different immunomodulatory molecules, mesenchymal stem cells (MSCs) play a significant role in the regulation of immune responses against tumor cells. Herein, the expression of major histocompatibility complex class I polypeptide-related sequence B (MIC B) as an immunomodulatory molecule was investigated on adipose-derived stem cells (ASCs) isolated from breast cancer patients (Stage II and III) and healthy individuals.
INTRODUCTION
Mesenchymal stem cells (MSCs) are multipotent stromal cells which are described as fibroblast-like cells in many different tissues with immune regulatory capability. [1, 2] The chronic inflammatory state of tumor site leads to the recruitment of different cell types such as MSCs through the expression of chemokines. [3, 4] These cells exert their immunomodulatory effects on immune cells resulting in increasing tumor cells development and progression. [5, 6] MSCs can inhibit cytotoxic effects of T cells on cervical cancer cells through the reduction of human leukocyte antigen Class I molecules expression. [7] Secretion of soluble factors and cell-to-cell contact are involved in MSCs immunomodulation though the exact mechanism is not well identified yet. [8] Similar to bone marrow MSCs, ASCs were also defined as important players orchestrating the tumor-promoting immune responses through the secretion of different mediators including interleukin-4 (IL-4), IL-10, and transforming growth factor β (TGF-β). [9] Natural-killer Group 2, member D, also known as Klrk1 (NKG2D), a C-type lectin-like receptor, is expressed on natural killer (NK), CD8+ T cells, and γδ+ T cells as an activating immune receptor. NKG2D ligands are polymorphic and structural homologs of major histocompatibility complex Class I heavy chains, but not associated with β2-microglobulin and lacks CD8 binding site, also does not present any antigen. These molecules are extensively expressed in various malignancies and viral-infected tissues but are rarely expressed in normal tissues. Human NKG2D ligands include major histocompatibility complex class I polypeptide-related sequence A and B (MICA and MICB) proteins and retinoic acid early transcripts-1 (RAET1), also known as UL-16 binding proteins (ULBP). In the mouse, NKG2D ligands include five different RAET1 isoforms, three different histocompatibility 60 (H60) isoforms, and one UL-16 binding protein 1 (MULT1) gene. [10] [11] [12] MIC B plays important roles in immunosurveillance of tumors by binding to NKG2D on immune cells such as NK and CD8 + T cells. [13] The expression of MIC B by tumor cells results also in antitumor immune responses of natural killer T cells (NKT) and gamma-delta T cells against tumor cells. [14] It has been shown that transplanted tumor cells expressing Rae1 and H60 were rejected in vivo. [15, 16] MIC B sheds by metalloproteases from tumor cells and releases to bloodstream or tissue culture medium as a soluble molecule in different malignancies. [17] [18] [19] Salih et al. have shown the presence of MIC B molecule in the sera of patients with hematopoietic or gastrointestinal malignancies. [17] It has been demonstrated that the soluble MIC B serum level is correlated with oral squamous cell carcinoma stage and patients survival. [19] Regarding the significant role of ASCs and MIC B in the tumor development, here, we proposed for the first time to investigate the MIC B expression in ASCs isolated from breast adipose tissue of breast cancer patients before and after treatment with IFN-γ and to detect the MIC B serum level in patients with pathological Stage II and III compared to normal individuals.
MATERIALS AND METHODS

Subjects
To assess the mRNA expression of MIC B, ASCs were isolated from adipose tissue of 15 breast cancer patients included eight patients with pathological Stage II and 7 with pathological Stage III. Data were compared to 8 healthy females who were undergoing cosmetic surgery and had no history of autoimmune disease or malignancy. To evaluate the serum level of MIC B, blood samples were obtained from 44 breast cancer patients, 22 with pathological Stage II and 22 with pathological Stage III and 21 age-matched healthy females. Sera were isolated after centrifugation and stored at −20°C.
All samples were obtained after getting informed consent. Clinicopathological characteristic of breast cancer patients are presented in Table 1 .
Adipose-derived stem cells isolation, characterization, and culture
Fragments of breast adipose tissue of breast cancer patients and normal individuals were washed with phosphate-buffered saline, minced with scissor, and digested with 0.2% collagenase I (GIBCO, USA) at 37°C for 45 min. The resulting suspension was centrifuged, and stromal cells were purified by Ficoll gradient (Biosera, UK) centrifugation, cultured in DMEM (GIBCO, USA) medium containing 10% fetal bovine serum (FBS) (GIBCO, USA) and penicillin/streptomycin (Biosera, UK). After 48 h, nonadherent cells were discarded and adherent cells were cultured. All ASCs used in this study were in fourth culture passage.
For characterization of the cells, flow cytometry analysis and differentiation were used as described previously. [9, 20] Briefly, 5 × 10 6 of ASCs were harvested and incubated for 30 min with phycoerythrin-conjugated mouse antihuman CD44, CD105, and CD166 (BD Biosciences, USA) and fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD14, CD34, and CD45 (BD Biosciences, USA) at room temperature (RT). Cells were stained with FITC-or PE-labeled mouse IgG as negative controls. Approximately 20,000 events were collected and further analyzed using WinMDI 2.5 software (Microsoft, Redmond, WA, USA). To show the stem cell characteristics of ASCs, they were differentiated to chondrocytes using chondrogenesis differentiation kit (STEMPRO Chondrogenesis Differentiation Kit, GIBCO, USA) and stained with 0.2% Safranin O after 2 weeks. 
RNA extraction and cDNA synthesis
Total RNA was extracted from ASCs stimulated with or without 1500U/ml IFN-γ using RNX plus (Cinagene, Iran). DNase (Fermentas, Canada) treatment was performed, and then, cDNA was generated using cDNA synthesis kit (Fermentas, Canada) based on the manufacture's transcript.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) method was performed using ABI step one system. Briefly, 2 μl cDNA was amplified in total volume of 20 μl containing 10 μl of 2X SYBR Green Master Mix (Fermentas, Canada), 7.4 μl DEPC-treated water and 0.3 μl of each 10 pmol forward and reverse primers. Thermal cycling was initiated with denaturation at 95°C for 10 min, followed by 50 cycles: denaturation at 95°C for 10 s, annealing, and extension at 55°C for 40 s. All data were compared to beta-actin housekeeping gene. Sequences of specific primers for qRT-PCR of MIC B (target gene) and β-actin (reference gene) were F: 5'CACCCAGGCTGCAGTTCACT3', R: 'CGGGAGTCTGAGGTACGAGAA3' and F: 5'GCCTTTGCCCATCCGC-3', R: 5'GCCGTAGCCGTTGTCG-3', respectively.
Enzyme-linked immunosorbent assay
The level of MIC B in the sera of breast cancer patients and normal individuals and the supernatant of ASCs was detected using MIC B human ELISA kit (Abcam, UK). For evaluation of supernatants, 3.5 × 10 4 ASCs were cultured in a volume of 400 μl DMEM containing10% FBS stimulated with 1500U/ml IFN-γ for 72 h. Then, 100 μl of standard, ASCs supernatant, and serum samples were added to the wells and incubated at 4°C for overnight and then washed 4 times. Then, 100 μl of biotinylated anti-MIC B was added to each well and washed 4 times after 1 h incubation at RT. A volume of 100 μl of streptavidin-conjugated HRP enzyme was added to each well, incubated for 45 min at RT, and then washed 4 times. After addition of 100 μl tetramethylbenzidine substrate solution, enzymatic reaction was stopped using 50 μl of stop solution, and the absorbance was measured at 450-620 nm in a microplate spectrophotometer.
Statistical analysis
The expression of MIC B mRNA was determined using 2 -ΔCT method. Intergroup differences estimated using Mann-Whitney and Kruskal-Wallis H nonparametric tests and considered significant if P < 0.05. All values are expressed as the mean ± standard error of the mean (SEM) Graphs is presented using GraphPad Prism (GraphPad Software Inc., San Diego, CA).
RESULTS
Characterization of adipose-derived stem cells
Before differentiation, ASCs were appeared with a spindle shape in culture and MSCs characteristic was demonstrated through both morphological changes and expression of chondrogenic genes postchondrogenic differentiation. [20] Flow cytometry characterization revealed that ASCs from both patients and controls were highly positive for the expressions of CD44, CD105, and CD166; however, they were negative for CD14, CD34, and CD45 expression. [9, 20] 
Major histocompatibility complex class I polypeptiderelated sequence B mRNA expression in cancer and normal adipose-derived stem cells before and after treatment with IFN-γ
The mRNA expression of MIC B was compared between normal, Stage II and Stage III ASCs. As it is shown in Figure 1 , the expression of MIC B in normal ASCs was approximately 2 fold higher than cancer ASCs. In addition, Stage II ASCs showed higher expression of MIC B compared to Stage III ASCs (2.5 fold). These differences were not statistically significant (P > 0.05).
Relative quantification of MIC B expression in ASCs was
conversely changed after stimulation with IFN-γ. As it is illustrated in Figure 1 , cancer ASCs showed approximately 3.5 fold higher expression of MIC B compared to normal ASCs after stimulation with IFN-γ. Stage III and Stage II ASCs expressed MIC B 3.6 and 3.1 fold higher than normal ASCs, respectively, after treatment the cells with IFN-γ (P > 0.05).
When we compared the mRNA expression of MIC B before and after stimulation with IFN-γ in each group of the cells, a positive trend of increase with pathological stage of breast cancer was found. Results showed 61 (P = 0.02), 13 (P = 0.01), and 3 (P > 0.05) fold higher expression of MIC B after stimulation compared to before stimulation with IFN-γ in Stage III, Stage II, and normal ASCs, respectively [ Figure 1 ]. 
Major histocompatibility complex class I polypeptide-related sequence B level in adipose-derived stem cells supernatant and sera of breast cancer patients and controls MIC B concentration in the supernatant of IFN-γ-stimulated
ASCs and sera of breast cancer patients and controls are depicted in Figures 2 and 3 
Level of major histocompatibility complex class I polypeptiderelated sequence B in breast cancer patients regarding grade disease and the age of patients
The expression of MIC B in different age groups and grades of the breast cancer patients were statistically analyzed. There was no significant correlation between the expression of this molecule and grade disease and the different ages of the patients studied.
DISCUSSION
The production of MIC B as one of the most frequently expressed human NKG2D ligands has been reported in different cancers. [18, 21] The expression of this molecule leads to the antitumor immune responses of various immune cells against tumor cells. [14] However, frequent stimulation of NKG2D receptor by its ligands results in downregulation of this receptor and the impairment of immune cells activation. [22, 23] Activated CD4+ T cells gain the ability to release NKG2D ligands and suppress CD8 + T cells function by downregulating NKG2D activating receptor. [24] Beside tumor cells, expression of NKG2D ligands including MIC A and MIC B and ULBPs is also demonstrated in stromal cells such as BMSCs. [25] BMSCs could inhibit CD8+ T cell proliferation and cytokine production by downregulating the expression of the NKG2D receptor through the expression of MIC A/B molecules and also soluble factors such as PGE2, IDO, and TGF-β. [26] Therefore, the blocking of MIC A/B molecule on BMSCs was led to the retrieval of CD8+ T cell function. [26] It is shown by Spaggiari et al. [27] and Poggi et al. [28] that BMSCs can dampen the surface expression of NKG2D on NK cells. [27, 28] We also demonstrated in our previous study that adipose-derived MSCs significantly reduced NKG2D+ and CD69+ NK cells (Accepted by cell Journal). Herein, in accordance with others, [25, 26] we for the first time showed that adipose-derived stem cells (ASCs) can produce MIC B molecule. Based on our results, the expression of MIC B in normal ASCs was approximately 2-fold higher than cancer ASCs. In addition, Stage II ASCs showed 2.5 fold higher expression of MIC B compared to Stage III ASCs.
As it has been well identified that IFN-γ is produced by immune cells in the tumor microenvironment and plays pivotal roles in the regulation of tumor progression, [29, 30] we proposed to stimulate ASCs by IFN-γ to investigate the MIC B expression.
Comparing the relative quantification of MIC B expression in normal, Stage II and Stage III ASCs before and after stimulation with IFN-γ, we showed that IFN-γ treatment changed the trend of MIC B expression in different ASCs. STAGE II and III ASCs showed higher expression of MIC B compared to normal ASCs significantly. When both stages were compared to each other, Stage III ASCs were higher producers of MIC B compared to Stage II after stimulation with IFN-γ. On the other hand, detection of soluble form of MIC B molecule in the supernatant of ASCs stimulated with IFN-γ showed that the concentration of this molecule in the supernatant of normal ASCs was higher than that from the cancer ASCs. Regarding the present report, by increasing the expression of MIC B on their surface but not shedding of this molecule, ASCs would play crucial roles in the tumor progression. It seems that by raising the stage of breast cancer increasing the expression of MIC ligands on ASCs will occur which probably leads to the higher rate of downregulation in NKG2D on NKG2D-expressing immune cells and consequently interrupting the immunity against tumor.
Human cancer cells as a mechanism of evasion shed NKG2D ligands into the bloodstream to downregulate the expression of NKG2D on NK, NKT, γδ, and CD8 + T cells, resulting in the reduction of tumor cells susceptibility to cytotoxicity of NKG2D positive lymphocytes. [22, 23, [31] [32] [33] On the other hand, to assurance that immune cells activate only against tumor but not healthy cells, the expression of NKG2D ligands must be exactly controlled. It is shown that posttranslational regulation of the mouse NKG2D ligand, MULT1, results in MULT1 ubiquitination and degradation in healthy cells. UV stress or heat shock decreases the ubiquitination of MULT1 which leads to the augmentation of cell surface expression of this molecule. [34] In addition, it is reported that if NKG2D ligands are expressed in normal tissues, their expression is in the lowest amount which cannot activate the immune cells. [35] Consistently, in the present study, results showed that the serum level of MIC B in healthy individuals was higher than both Stage II and III breast cancer patients. On the other words, MIC B might have more shedding to the serum in healthy individuals to guarantee that NK cells do not activate against healthy cells. There are conflicting reports because in colon adenocarcinoma, the elevated level of soluble MIC in serum was reported. [36] Also in oral squamous cell carcinoma, the increased serum level of MIC B was observed in Stage IV compared to normal individuals which was associated with decreased survival rate in the patients. [19] A possible explanation for this discrepancy could be the type of cancer and may be best explained by differences in the tumor growth pattern.
CONCLUSION
The MIC A/B expression by ASCs may represent one of the crucial mechanisms whereby ASC modulate immune cell function in the tumor microenvironment. This prediction will undoubtedly require further relevant studies for more confirmation. Investigating the expression of other ligands of NKG2D by ASCs seems to be beneficial to identify NKG2D ligands-dependent immunomodulatory roles of ASCs in the tumor microenvironment.
